康泰医学
(300869)
| 流通市值：31.88亿 | | | 总市值：48.50亿 |
| 流通股本：2.64亿 | | | 总股本：4.02亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 100,279,216.75 | 468,004,884.41 | 343,992,692.71 | 217,549,459.94 |
| 营业收入 | 100,279,216.75 | 468,004,884.41 | 343,992,692.71 | 217,549,459.94 |
| 二、营业总成本 | 114,012,396.72 | 496,009,962.87 | 335,255,538.73 | 192,423,187.84 |
| 营业成本 | 48,347,008.24 | 243,142,442.81 | 155,727,261.42 | 86,114,414.21 |
| 税金及附加 | 2,185,955.66 | 7,709,699.75 | 6,261,146.53 | 4,931,403.2 |
| 销售费用 | 19,589,070.3 | 109,966,081.06 | 79,276,561.67 | 42,412,618.74 |
| 管理费用 | 10,638,696.28 | 39,475,990.05 | 27,165,697.13 | 17,112,193.37 |
| 研发费用 | 21,701,198.82 | 91,658,946.04 | 69,070,735.32 | 46,481,133.59 |
| 财务费用 | 11,550,467.42 | 4,056,803.16 | -2,245,863.34 | -4,628,575.27 |
| 其中:利息费用 | - | 37,428,972.59 | - | - |
| 其中:利息收入 | - | 49,801,528.24 | - | - |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,334,068.88 | 1,773,267.48 | 3,329,630.79 | 2,752,724.31 |
| 加:投资收益 | 2,016,982.9 | 16,729,120.38 | 6,633,235.12 | 849,480.1 |
| 资产处置收益 | - | 171.89 | 5,857.18 | 0 |
| 资产减值损失(新) | - | -28,148,237.76 | -18,155,116.54 | -16,022,591.5 |
| 信用减值损失(新) | 239,253.89 | 1,354,502.84 | -117,804.32 | 107,054.65 |
| 其他收益 | 310,190.79 | 9,963,375.98 | 9,644,780.94 | 5,523,541.59 |
| 四、营业利润 | -8,832,683.51 | -26,332,877.65 | 10,077,737.15 | 18,336,481.25 |
| 加:营业外收入 | 273,863.32 | 1,086,164.45 | 688,444.12 | 495,178.41 |
| 减:营业外支出 | 152,586.65 | 1,639,226.21 | 655,257.13 | 338,919 |
| 五、利润总额 | -8,711,406.84 | -26,885,939.41 | 10,110,924.14 | 18,492,740.66 |
| 减:所得税费用 | -469,636.88 | -2,462,078.36 | 711,081.74 | 1,555,167.49 |
| 六、净利润 | -8,241,769.96 | -24,423,861.05 | 9,399,842.4 | 16,937,573.17 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -8,241,769.96 | -24,423,861.05 | 9,399,842.4 | 16,937,573.17 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -8,241,769.96 | -24,423,861.05 | 9,399,842.4 | 16,937,573.17 |
| 扣除非经常损益后的净利润 | -12,231,865.25 | -47,342,312.74 | -3,397,211.81 | 12,453,493.18 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | -0.06 | 0.02 | 0.04 |
| (二)稀释每股收益 | -0.02 | -0.06 | 0.02 | 0.04 |
| 八、其他综合收益 | -806,737.63 | -625,845.49 | -245,172.4 | 125,719.53 |
| 归属于母公司股东的其他综合收益 | -806,737.63 | -625,845.49 | -245,172.4 | 125,719.53 |
| 九、综合收益总额 | -9,048,507.59 | -25,049,706.54 | 9,154,670 | 17,063,292.7 |
| 归属于母公司股东的综合收益总额 | -9,048,507.59 | -25,049,706.54 | 9,154,670 | 17,063,292.7 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-30 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |